Chapter 6 Vascular Calcification Inhibitors In Relation To Cardiovascular Disease With Special Emphasis On Fetuin-A In Chronic Kidney Disease

Advances in Clinical Chemistry

Volumn 46, Issue , 2008, Pages 217-262

  Suliman, Mohamed E ^a   García López, Elvia ^a   Anderstam, Björn ^a   Lindholm, Bengt ^a   Stenvinkel, Peter ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2HS GLYCOPROTEIN; BMP7 PROTEIN, HUMAN; CALCIUM BINDING PROTEIN; MATRIX GLA PROTEIN; OSTEOGENIC PROTEIN 1; OSTEOPONTIN; OSTEOPROTEGERIN; PLASMA PROTEIN; SCLEROPROTEIN; TNFRSF11B PROTEIN, HUMAN; UNCLASSIFIED DRUG;

CALCINOSIS; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; GENETICS; HUMAN; INFLAMMATION; KIDNEY DISEASE; METABOLIC SYNDROME X; PHYSIOLOGY; REVIEW; VASCULAR DISEASE;

BLOOD PROTEINS; BONE MORPHOGENETIC PROTEIN 7; CALCINOSIS; CALCIUM-BINDING PROTEINS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; EXTRACELLULAR MATRIX PROTEINS; HUMANS; INFLAMMATION; KIDNEY DISEASES; METABOLIC SYNDROME X; OSTEOPONTIN; OSTEOPROTEGERIN; VASCULAR DISEASES;

EID: 53849147218     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(08)00406-X     Document Type: Review

References (244)

1. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 Suppl. 5 (1998) S112-S119
2. Stenvinkel P., Pecoits-Filho R., and Lindholm B. Coronary artery disease in end-stage renal disease: No longer a simple plumbing problem. J Am Soc Nephrol 14 7 (2003) 1927-1939
3. London G.M., Guerin A.P., Marchais S.J., Metivier F., Pannier B., and Adda H. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18 9 (2003) 1731-1740
4. Ibels L.S., Stewart J.H., Mahony J.F., Neale F.C., and Sheil A.G. Occlusive arterial disease in uraemic and haemodialysis patients and renal transplant recipients. A study of the incidence of arterial disease and of the prevalence of risk factors implicated in the pathogenesis of arteriosclerosis. Q J Med 46 182 (1977) 197-214
5. Guerin A.P., London G.M., Marchais S.J., and Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15 7 (2000) 1014-1021
6. Goodman W.G., Goldin J., Kuizon B.D., Yoon C., Gales B., Sider D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 20 (2000) 1478-1483
7. Oh J., Wunsch R., Turzer M., Bahner M., Raggi P., Querfeld U., et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106 1 (2002) 100-105
8. Nelson R.G., Gohdes D.M., Everhart J.E., Hartner J.A., Zwemer F.L., Pettitt D.J., et al. Lower-extremity amputations in NIDDM. 12-yr follow-up study in Pima Indians. Diabetes Care 11 1 (1988) 8-16
9. Blacher J., Guerin A.P., Pannier B., Marchais S.J., and London G.M. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38 4 (2001) 938-942
10. Wang A.Y., Wang M., Woo J., Lam C.W., Li P.K., Lui S.F., et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: A prospective study. J Am Soc Nephrol 14 1 (2003) 159-168
11. Lee N.K., Sowa H., Hinoi E., Ferron M., Ahn J.D., Confavreux C., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 130 3 (2007) 456-469
12. Boström K., Watson K.E., Horn S., Wortham C., Herman I.M., and Demer L.L. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 91 4 (1993) 1800-1809
13. Reslerova M., and Moe S.M. Vascular calcification in dialysis patients: Pathogenesis and consequences. Am J Kidney Dis 41 3 Suppl. 1 (2003) S96-S99
14. Chen N.X., and Moe S.M. Vascular calcification in chronic kidney disease. Semin Nephrol 24 1 (2004) 61-68
15. Moe S.M., and Chen N.X. Vascular calcification in end stage renal disease. Clin Calcium 12 10 (2002) 1417-1422
16. Moe S.M., O'Neill K.D., Duan D., Ahmed S., Chen N.X., Leapman S.B., et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61 2 (2002) 638-647
17. Johnson R.C., Leopold J.A., and Loscalzo J. Vascular calcification: Pathobiological mechanisms and clinical implications. Circ Res 99 10 (2006) 1044-1059
18. Mazzaferro S., Pasquali M., Pugliese F., Barresi G., Carbone I., Francone M., et al. Serum levels of calcification inhibition proteins and coronary artery calcium score: Comparison between transplantation and dialysis. Am J Nephrol 27 1 (2007) 75-83
19. El-Abbadi M., and Giachelli C.M. Mechanisms of vascular calcification. Adv Chronic Kidney Dis 14 1 (2007) 54-66
20. Schäfer C., Heiss A., Schwarz A., Westenfeld R., Ketteler M., Floege J., et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112 3 (2003) 357-366
21. Abedin M., Tintut Y., and Demer L.L. Vascular calcification: Mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 24 7 (2004) 1161-1170
22. Boström K. Insights into the mechanism of vascular calcification. Am J Cardiol 88 2A (2001) 20E-22E
23. Chen N.X., and Moe S.M. Uremic vascular calcification. J Investig Med 54 7 (2006) 380-384
24. Ketteler M., Westenfeld R., Schlieper G., and Brandenburg V. Pathogenesis of vascular calcification in dialysis patients. Clin Exp Nephrol 9 4 (2005) 265-270
25. Block G.A., and Port F.K. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35 6 (2000) 1226-1237
26. Giachelli C.M. Vascular calcification: In vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 14 9 Suppl. 4 (2003) S300-S304
27. Vattikuti R., and Towler D.A. Osteogenic regulation of vascular calcification: An early perspective. Am J Physiol Endocrinol Metab 286 5 (2004) E686-E696
28. Hisar I., Ileri M., Yetkin E., Tandogan I., Cehreli S., Atak R., et al. Aortic valve calcification: Its significance and limitation as a marker for coronary artery disease. Angiology 53 2 (2002) 165-169
29. Ortlepp J.R., Schmitz F., Bozoglu T., Hanrath P., and Hoffmann R. Cardiovascular risk factors in patients with aortic stenosis predict prevalence of coronary artery disease but not of aortic stenosis: An angiographic pair matched case-control study. Heart 89 9 (2003) 1019-1022
30. Stewart B.F., Siscovick D., Lind B.K., Gardin J.M., Gottdiener J.S., Smith V.E., et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 29 3 (1997) 630-634
31. Yamamoto H., Shavelle D., Takasu J., Lu B., Mao S.S., Fischer H., et al. Valvular and thoracic aortic calcium as a marker of the extent and severity of angiographic coronary artery disease. Am Heart J 146 1 (2003) 153-159
32. Demer L.L. Vascular calcification and osteoporosis: Inflammatory responses to oxidized lipids. Int J Epidemiol 31 4 (2002) 737-741
33. Davies M.R., and Hruska K.A. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 60 2 (2001) 472-479
34. Cheng S.L., Shao J.S., Charlton-Kachigian N., Loewy A.P., and Towler D.A. MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem 278 46 (2003) 45969-45977
35. Shao J.S., Cheng S.L., Charlton-Kachigian N., Loewy A.P., and Towler D.A. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 278 50 (2003) 50195-50202
36. Towler D.A., Bidder M., Latifi T., Coleman T., and Semenkovich C.F. Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem 273 46 (1998) 30427-30434
37. Tanimura A., McGregor D.H., and Anderson H.C. Matrix vesicles in atherosclerotic calcification. Proc Soc Exp Biol Med 172 2 (1983) 173-177
38. Lehto S., Niskanen L., Suhonen M., Ronnemaa T., and Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 16 8 (1996) 978-983
39. London G.M., and Drueke T.B. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 51 6 (1997) 1678-1695
40. Goldsmith D., Ritz E., and Covic A. Vascular calcification: A stiff challenge for the nephrologist: Does preventing bone disease cause arterial disease?. Kidney Int 66 4 (2004) 1315-1333
41. Ketteler M., Gross M.L., and Ritz E. Calcification and cardiovascular problems in renal failure. Kidney Int Suppl 94 (2005) S120-S127
42. Qunibi W.Y., Nolan C.A., and Ayus J.C. Cardiovascular calcification in patients with end-stage renal disease: A century-old phenomenon. Kidney Int Suppl 82 (2002) 73-80
43. Kuzela D.C., Huffer W.E., Conger J.D., Winter S.D., and Hammond W.S. Soft tissue calcification in chronic dialysis patients. Am J Pathol 86 2 (1977) 403-424
44. Maher E.R., Young G., Smyth-Walsh B., Pugh S., and Curtis J.R. Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 2 8564 (1987) 875-877
45. Mazzaferro S., Coen G., Bandini S., Borgatti P.P., Ciaccheri M., Diacinti D., et al. Role of ageing, chronic renal failure and dialysis in the calcification of mitral annulus. Nephrol Dial Transplant 8 4 (1993) 335-340
46. Braun J., Oldendorf M., Moshage W., Heidler R., Zeitler E., and Luft F.C. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27 3 (1996) 394-401
47. Floege J., and Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant 19 Suppl. 5 (2004) V59-V66
48. Eifinger F., Wahn F., Querfeld U., Pollok M., Gevargez A., Kriener P., et al. Coronary artery calcifications in children and young adults treated with renal replacement therapy. Nephrol Dial Transplant 15 11 (2000) 1892-1894
49. Schwarz U., Buzello M., Ritz E., Stein G., Raabe G., Wiest G., et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15 2 (2000) 218-223
50. Goodman W.G., London G., Amann K., Block G.A., Giachelli C., Hruska K.A., et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 43 3 (2004) 572-579
51. Foley R.N., and Parfrey P.S. Cardiovascular disease and mortality in ESRD. J Nephrol 11 5 (1998) 239-245
52. Sangiorgi G., Rumberger J.A., Severson A., Edwards W.D., Gregoire J., Fitzpatrick L.A., et al. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: A histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol 31 1 (1998) 126-133
53. Raggi P., Callister T.Q., Cooil B., He Z.X., Lippolis N.J., Russo D.J., et al. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation 101 8 (2000) 850-855
54. Burke A.P., Taylor A., Farb A., Malcom G.T., and Virmani R. Coronary calcification: Insights from sudden coronary death victims. Z Kardiol 89 Suppl. 2 (2000) 49-53
55. Shanahan C.M., Cary N.R., Salisbury J.R., Proudfoot D., Weissberg P.L., and Edmonds M.E. Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis: Evidence for smooth muscle cell-mediated vascular calcification. Circulation 100 21 (1999) 2168-2176
56. Speer M.Y., and Giachelli C.M. Regulation of cardiovascular calcification. Cardiovasc Pathol 13 2 (2004) 63-70
57. Heremans J.F. The globulins of the gamma system of human plasma. Bull Schweiz Akad Med Wiss 17 (1961) 119-138
58. Schmid K., and Burgi W. Preparation and properties of the human plasma Ba-alpha2-glycoproteins. Biochim Biophys Acta 47 (1961) 440-453
59. Triffitt J.T., Gebauer U., Ashton B.A., Owen M.E., and Reynolds J.J. Origin of plasma alpha2HS-glycoprotein and its accumulation in bone. Nature 262 5565 (1976) 226-227
60. Ketteler M., Wanner C., Metzger T., Bongartz P., Westenfeld R., Gladziwa U., et al. Deficiencies of calcium-regulatory proteins in dialysis patients: A novel concept of cardiovascular calcification in uremia. Kidney Int Suppl 84 (2003) S84-S87
61. Falquerho L., Patey G., Paquereau L., Rossi V., Lahuna O., Szpirer J., et al. Primary structure of the rat gene encoding an inhibitor of the insulin receptor tyrosine kinase. Gene 98 2 (1991) 209-216
62. Nawratil P., Lenzen S., Kellermann J., Haupt H., Schinke T., Muller-Esterl W., et al. Limited proteolysis of human alpha2-HS glycoprotein/fetuin. Evidence that a chymotryptic activity can release the connecting peptide. J Biol Chem 271 49 (1996) 31735-31741
63. Haglund A.C., Ek B., and Ek P. Phosphorylation of human plasma alpha2-Heremans-Schmid glycoprotein (human fetuin) in vivo. Biochem J 357 Pt. 2 (2001) 437-445
64. Spiro R.G. Studies on fetuin, a glycoprotein of fetal serum: Isolation, chemical composition, and physiochemical properties. J Biol Chem 235 10 (1960) 2860-2869
65. Olivier E., Soury E., Ruminy P., Husson A., Parmentier F., Daveau M., et al. Fetuin-B, a second member of the fetuin family in mammals. Biochem J 350 Pt. 2 (2000) 589-597
66. Denecke B., Graber S., Schafer C., Heiss A., Woltje M., and Jahnen-Dechent W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J 376 Pt. 1 (2003) 135-145
67. Ix J.H., Shlipak M.G., Brandenburg V.M., Ali S., Ketteler M., and Whooley M.A. Association between human fetuin-A and the metabolic syndrome: Data from the Heart and Soul Study. Circulation 113 14 (2006) 1760-1767
68. Szweras M., Liu D., Partridge E.A., Pawling J., Sukhu B., Clokie C., et al. alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. J Biol Chem 277 22 (2002) 19991-19997
69. Schinke T., Amendt C., Trindl A., Poschke O., Muller-Esterl W., and Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 271 34 (1996) 20789-20796
70. Heiss A., DuChesne A., Denecke B., Grotzinger J., Yamamoto K., Renne T., et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 278 15 (2003) 13333-13341
71. Ohnishi T., Nakamura O., Arakaki N., and Daikuhara Y. Effect of phosphorylated rat fetuin on the growth of hepatocytes in primary culture in the presence of human hepatocyte-growth factor. Evidence that phosphorylated fetuin is a natural modulator of hepatocyte-growth factor. Eur J Biochem 243 3 (1997) 753-761
72. Demetriou M., Binkert C., Sukhu B., Tenenbaum H.C., and Dennis J.W. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem 271 22 (1996) 12755-12761
73. Mathews S.T., Singh G.P., Ranalletta M., Cintron V.J., Qiang X., Goustin A.S., et al. Improved insulin sensitivity and resistance to weight gain in mice null for the AHSG gene. Diabetes 51 8 (2002) 2450-2458
74. Price P.A., Thomas G.R., Pardini A.W., Figueira W.F., Caputo J.M., and Williamson M.K. Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix gamma-carboxyglutamic acid protein in the serum of etidronate-treated rats. J Biol Chem 277 6 (2002) 3926-3934
75. Price P.A., Williamson M.K., Nguyen T.M., and Than T.N. Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. J Biol Chem 279 3 (2004) 1594-1600
76. Reynolds J.L., Skepper J.N., McNair R., Kasama T., Gupta K., Weissberg P.L., et al. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 16 10 (2005) 2920-2930
77. Lebreton J.P., Joisel F., Raoult J.P., Lannuzel B., Rogez J.P., and Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: Evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 64 4 (1979) 1118-1129
78. Wang H., Zhang M., Soda K., Sama A., and Tracey K.J. Fetuin protects the fetus from TNF. Lancet 350 9081 (1997) 861-862
79. Ombrellino M., Wang H., Yang H., Zhang M., Vishnubhakat J., Frazier A., et al. Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to carrageenan. Shock 15 3 (2001) 181-185
80. Daveau M., Christian D., Julen N., Hiron M., Arnaud P., and Lebreton J.P. The synthesis of human alpha-2-HS glycoprotein is down-regulated by cytokines in hepatoma HepG2 cells. FEBS Lett 241 1-2 (1988) 191-194
81. Gangneux C., Daveau M., Hiron M., Derambure C., Papaconstantinou J., and Salier J.P. The inflammation-induced down-regulation of plasma Fetuin-A (alpha2HS-Glycoprotein) in liver results from the loss of interaction between long C/EBP isoforms at two neighbouring binding sites. Nucleic Acids Res 31 20 (2003) 5957-5970
82. Wang H., Zhang M., Bianchi M., Sherry B., Sama A., and Tracey K.J. Fetuin (alpha2-HS-glycoprotein) opsonizes cationic macrophagedeactivating molecules. Proc Natl Acad Sci USA 95 24 (1998) 14429-14434
83. Chen N.X., and Moe S.M. Arterial calcification in diabetes. Curr Diab Rep 3 1 (2003) 28-32
84. van Oss C.J., Gillman C.F., Bronson P.M., and Border J.R. Opsonic properties of human serum alpha-2 hs glycoprotein. Immunol Commun 3 4 (1974) 329-335
85. Terkeltaub R.A., Santoro D.A., Mandel G., and Mandel N. Serum and plasma inhibit neutrophil stimulation by hydroxyapatite crystals. Evidence that serum alpha 2-HS glycoprotein is a potent and specific crystal-bound inhibitor. Arthritis Rheum 31 9 (1988) 1081-1089
86. Baskies A.M., Chretien P.B., Weiss J.F., Makuch R.W., Beveridge R.A., Catalona W.J., et al. Serum glycoproteins in cancer patients: First report of correlations with in vitro and in vivo parameters of cellular immunity. Cancer 45 12 (1980) 3050-3060
87. Kalabay L., Cseh K., Jakab L., Pozsonyi T., Jakab L., Benedek S., et al. Diagnostic value of the determination of serum alpha2-HS-glycoprotein. Orv Hetil 133 25 (1992) 1553-1554 1559-1560
88. Kalabay L., Jakab L., Prohaszka Z., Fust G., Benko Z., Telegdy L., et al. Human fetuin/alpha2HS-glycoprotein level as a novel indicator of liver cell function and short-term mortality in patients with liver cirrhosis and liver cancer. Eur J Gastroenterol Hepatol 14 4 (2002) 389-394
89. Ketteler M., Bongartz P., Westenfeld R., Wildberger J.E., Mahnken A.H., Bohm R., et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet 361 9360 (2003) 827-833
90. Stenvinkel P., Wang K., Qureshi A.R., Axelsson J., Pecoits-Filho R., Gao P., et al. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int 67 6 (2005) 2383-2392
91. Wang A.Y., Woo J., Lam C.W., Wang M., Chan I.H., Gao P., et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 20 8 (2005) 1676-1685
92. Hermans M.M., Brandenburg V., Ketteler M., Kooman J.P., van der Sande F.M., Boeschoten E.W., et al. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int 72 2 (2007) 202-207
93. Merx M.W., Schafer C., Westenfeld R., Brandenburg V., Hidajat S., Weber C., et al. Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. J Am Soc Nephrol 16 11 (2005) 3357-3364
94. Stompor T., Pasowicz M., Sullowicz W., Dembinska-Kiec A., Janda K., Wojcik K., et al. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis 41 1 (2003) 203-211
95. Asanuma Y., Oeser A., Shintani A.K., Turner E., Olsen N., Fazio S., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349 25 (2003) 2407-2415
96. Parhami F., Tintut Y., Ballard A., Fogelman A.M., and Demer L.L. Leptin enhances the calcification of vascular cells: Artery wall as a target of leptin. Circ Res 88 9 (2001) 954-960
97. Spronk H.M., Soute B.A., Schurgers L.J., Cleutjens J.P., Thijssen H.H., De Mey J.G., et al. Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. Biochem Biophys Res Commun 289 2 (2001) 485-490
98. Tintut Y., Patel J., Parhami F., and Demer L.L. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 102 21 (2000) 2636-2642
99. Davies M.R., Lund R.J., and Hruska K.A. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 14 6 (2003) 1559-1567
100. Nitta K., Akiba T., Uchida K., Kawashima A., Yumura W., Kabaya T., et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 42 2 (2003) 303-309
101. Auberger P., Falquerho L., Contreres J.O., Pages G., Le Cam G., Rossi B., et al. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 58 4 (1989) 631-640
102. Mathews S.T., Chellam N., Srinivas P.R., Cintron V.J., Leon M.A., Goustin A.S., et al. Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol 164 1-2 (2000) 87-98
103. Srinivas P.R., Wagner A.S., Reddy L.V., Deutsch D.D., Leon M.A., Goustin A.S., et al. Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 7 11 (1993) 1445-1455
104. Cintron V.J., Ko M.S., Chi K.D., Gross J.P., Srinivas P.R., Goustin A.S., et al. Genetic mapping and functional studies of a natural inhibitor of the insulin receptor tyrosine kinase: The mouse ortholog of human alpha2-HS glycoprotein. Int J Exp Diabetes Res 1 4 (2001) 249-263
105. Mathews S.T., Rakhade S., Zhou X., Parker G.C., Coscina D.V., and Grunberger G. Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun 350 2 (2006) 437-443
106. Stefan N., Hennige A.M., Staiger H., Machann J., Schick F., Krober S.M., et al. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29 4 (2006) 853-857
107. Lavebratt C., Dungner E., and Hoffstedt J. Polymorphism of the AHSG gene is associated with increased adipocyte beta2-adrenoceptor function. J Lipid Res 46 10 (2005) 2278-2281
108. Lavebratt C., Wahlqvist S., Nordfors L., Hoffstedt J., and Arner P. AHSG gene variant is associated with leanness among Swedish men. Hum Genet 117 1 (2005) 54-60
109. Dahlman I., Eriksson P., Kaaman M., Jiao H., Lindgren C.M., Kere J., et al. alpha2-Heremans-Schmid glycoprotein gene polymorphisms are associated with adipocyte insulin action. Diabetologia 47 11 (2004) 1974-1979
110. Siddiq A., Lepretre F., Hercberg S., Froguel P., and Gibson F. A synonymous coding polymorphism in the alpha2-Heremans-schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. Diabetes 54 8 (2005) 2477-2481
111. Hermans M.M., Brandenburg V., Ketteler M., Kooman J.P., van der Sande F.M., Gladziwa U., et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 21 5 (2006) 1293-1299
112. Ix J.H., Chertow G.M., Shlipak M.G., Brandenburg V.M., Ketteler M., and Whooley M.A. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: Data from the Heart and Soul Study. Circulation 115 19 (2007) 2533-2539
113. Ix J.H., Chertow G.M., Shlipak M.G., Brandenburg V.M., Ketteler M., and Whooley M.A. Fetuin-A and kidney function in persons with coronary artery disease-data from the heart and soul study. Nephrol Dial Transplant 21 8 (2006) 2144-2151
114. Odamaki M., Shibata T., Takita T., and Kumagai H. Serum fetuin-A and aortic calcification in hemodialysis patients. Kidney Int 68 6 (2005) 2915-2916
115. Lowrie E.G., and Lew N.L. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15 5 (1990) 458-482
116. Foley R.N., Parfrey P.S., Harnett J.D., Kent G.M., Murray D.C., and Barre P.E. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 7 5 (1996) 728-736
117. Cooper B.A., Penne E.L., Bartlett L.H., and Pollock C.A. Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD. Am J Kidney Dis 43 1 (2004) 61-66
118. Stenvinkel P., Heimbürger O., Paultre F., Diczfalusy U., Wang T., Berglund L., et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55 5 (1999) 1899-1911
119. Moe S.M., and Chen N.X. Inflammation and vascular calcification. Blood Purif 23 1 (2005) 64-71
120. Tintut Y., Patel J., Territo M., Saini T., Parhami F., and Demer L.L. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation 105 5 (2002) 650-655
121. Pecoits-Filho R., Nordfors L., Heimbürger O., Lindholm B., Anderstam B., Marchlewska A., et al. Soluble leptin receptors and serum leptin in end-stage renal disease: Relationship with inflammation and body composition. Eur J Clin Invest 32 11 (2002) 811-817
122. Moe S.M., Reslerova M., Ketteler M., O'Neill K., Duan D., Koczman J., et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 67 6 (2005) 2295-2304
123. Mehrotra R., Westenfeld R., Christenson P., Budoff M., Ipp E., Takasu J., et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: Relationship with coronary artery calcification. Kidney Int 67 3 (2005) 1070-1077
124. Fiore C.E., Celotta G., Politi G.G., Di Pino L., Castelli Z., Mangiafico R.A., et al. Association of high alpha(2)-Heremans-Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. Atherosclerosis 195 1 (2007) 110-115
125. Rauth G., Poschke O., Fink E., Eulitz M., Tippmer S., Kellerer M., et al. The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. Eur J Biochem 204 2 (1992) 523-529
126. Katz R., Wong N.D., Kronmal R., Takasu J., Shavelle D.M., Probstfield J.L., et al. Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 113 17 (2006) 2113-2119
127. Meigs J.B., Larson M.G., D'Agostino R.B., Levy D., Clouse M.E., Nathan D.M., et al. Coronary artery calcification in type 2 diabetes and insulin resistance: The framingham offspring study. Diabetes Care 25 8 (2002) 1313-1319
128. Ketteler M. Fetuin-A and extraosseous calcification in uremia. Curr Opin Nephrol Hypertens 14 4 (2005) 337-342
129. Spiegel D.M., Raggi P., Smits G., and Block G.A. Factors associated with mortality in patients new to haemodialysis. Nephrol Dial Transplant 22 12 (2007) 3568-3572
130. Moe S.M., O'Neill K.D., Fineberg N., Persohn S., Ahmed S., Garrett P., et al. Assessment of vascular calcification in ESRD patients using spiral CT. Nephrol Dial Transplant 18 6 (2003) 1152-1158
131. Osawa M., Yuasa I., Kitano T., Henke J., Kaneko M., Udono T., et al. Haplotype analysis of the human alpha2-HS glycoprotein (fetuin) gene. Ann Hum Genet 65 Pt. 1 (2001) 27-34
132. Lehtinen A.B., Burdon K.P., Lewis J.P., Langefeld C.D., Ziegler J.T., Rich S.S., et al. Association of alpha2-Heremans-Schmid glycoprotein polymorphisms with subclinical atherosclerosis. J Clin Endocrinol Metab 92 1 (2007) 345-352
133. Osawa M., Tian W., Horiuchi H., Kaneko M., and Umetsu K. Association of alpha2-HS glycoprotein (AHSG, fetuin-A) polymorphism with AHSG and phosphate serum levels. Hum Genet 116 3 (2005) 146-151
134. Price P.A., and Williamson M.K. Primary structure of bovine matrix Gla protein, a new vitamin K-dependent bone protein. J Biol Chem 260 28 (1985) 14971-14975
135. Proudfoot D., and Shanahan C.M. Molecular mechanisms mediating vascular calcification: Role of matrix Gla protein. Nephrology 11 5 (2006) 455-461
136. Farzaneh-Far A., Proudfoot D., Weissberg P.L., and Shanahan C.M. Matrix gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. Biochem Biophys Res Commun 277 3 (2000) 736-740
137. Shanahan C.M., Cary N.R., Metcalfe J.C., and Weissberg P.L. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 93 6 (1994) 2393-2402
138. Boström K., Tsao D., Shen S., Wang Y., and Demer L.L. Matrix GLA protein modulates differentiation induced by bone morphogenetic protein-2 in C3H10T1/2 cells. J Biol Chem 276 17 (2001) 14044-14052
139. Zebboudj A.F., Imura M., and Bostrom K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 277 6 (2002) 4388-4394
140. Moe S.M., and Chen N.X. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 95 6 (2004) 560-567
141. Sweatt A., Sane D.C., Hutson S.M., and Wallin R. Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats. J Thromb Haemost 1 1 (2003) 178-185
142. Schinke T., and Karsenty G. Vascular calcification-a passive process in need of inhibitors. Nephrol Dial Transplant 15 9 (2000) 1272-1274
143. Luo G., Ducy P., McKee M.D., Pinero G.J., Loyer E., Behringer R.R., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386 6620 (1997) 78-81
144. Munroe P.B., Olgunturk R.O., Fryns J.P., Van Maldergem L., Ziereisen F., Yuksel B., et al. Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nat Genet 21 1 (1999) 142-144
145. Jie K.S., Bots M.L., Vermeer C., Witteman J.C., and Grobbee D.E. Vitamin K intake and osteocalcin levels in women with and without aortic atherosclerosis: A population-based study. Atherosclerosis 116 1 (1995) 117-123
146. Geleijnse J.M., Vermeer C., Grobbee D.E., Schurgers L.J., Knapen M.H., van der Meer I.M., et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: The Rotterdam Study. J Nutr 134 11 (2004) 3100-3105
147. Price P.A., Faus S.A., and Williamson M.K. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 18 9 (1998) 1400-1407
148. Yagami K., Suh J.Y., Enomoto-Iwamoto M., Koyama E., Abrams W.R., Shapiro I.M., et al. Matrix GLA protein is a developmental regulator of chondrocyte mineralization and, when constitutively expressed, blocks endochondral and intramembranous ossification in the limb. J Cell Biol 147 5 (1999) 1097-1108
149. Koos R., Mahnken A.H., Muhlenbruch G., Brandenburg V., Pflueger B., Wildberger J.E., et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol 96 6 (2005) 747-749
150. Schurgers L.J., Aebert H., Vermeer C., Bultmann B., and Janzen J. Oral anticoagulant treatment: Friend or foe in cardiovascular disease?. Blood 104 10 (2004) 3231-3232
151. Coates T., Kirkland G.S., Dymock R.B., Murphy B.F., Brealey J.K., Mathew T.H., et al. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 32 3 (1998) 384-391
152. Murshed M., Schinke T., McKee M.D., and Karsenty G. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 165 5 (2004) 625-630
153. Jono S., Ikari Y., Vermeer C., Dissel P., Hasegawa K., Shioi A., et al. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost 91 4 (2004) 790-794
154. Braam L.A., Dissel P., Gijsbers B.L., Spronk H.M., Hamulyak K., Soute B.A., et al. Assay for human matrix gla protein in serum: Potential applications in the cardiovascular field. Arterioscler Thromb Vasc Biol 20 5 (2000) 1257-1261
155. O'Donnell C.J., Shea M.K., Price P.A., Gagnon D.R., Wilson P.W., Larson M.G., et al. Matrix Gla protein is associated with risk factors for atherosclerosis but not with coronary artery calcification. Arterioscler Thromb Vasc Biol 26 12 (2006) 2769-2774
156. Herrmann S.M., Whatling C., Brand E., Nicaud V., Gariepy J., Simon A., et al. Polymorphisms of the human matrix gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol 20 11 (2000) 2386-2393
157. Farzaneh-Far A., Davies J.D., Braam L.A., Spronk H.M., Proudfoot D., Chan S.W., et al. A polymorphism of the human matrix gamma-carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. J Biol Chem 276 35 (2001) 32466-32473
158. Brancaccio D., Biondi M.L., Gallieni M., Turri O., Galassi A., Cecchini F., et al. Matrix GLA protein gene polymorphisms: Clinical correlates and cardiovascular mortality in chronic kidney disease patients. Am J Nephrol 25 6 (2005) 548-552
159. Raisz L.G. Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest 115 12 (2005) 3318-3325
160. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89 2 (1997) 309-319
161. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273 23 (1998) 14363-14367
162. Price P.A., June H.H., Buckley J.R., and Williamson M.K. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 21 10 (2001) 1610-1616
163. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 9 (1998) 1260-1268
164. Zhang J., Fu M., Myles D., Zhu X., Du J., Cao X., et al. PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 521 1-3 (2002) 180-184
165. Schoppet M., Preissner K.T., and Hofbauer L.C. RANK ligand and osteoprotegerin: Paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 22 4 (2002) 549-553
166. Dhore C.R., Cleutjens J.P., Lutgens E., Cleutjens K.B., Geusens P.P., Kitslaar P.J., et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 21 12 (2001) 1998-2003
167. Min H., Morony S., Sarosi I., Dunstan C.R., Capparelli C., Scully S., et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192 4 (2000) 463-474
168. Browner W.S., Lui L.Y., and Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86 2 (2001) 631-637
169. Jono S., Ikari Y., Shioi A., Mori K., Miki T., Hara K., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106 10 (2002) 1192-1194
170. Schoppet M., Sattler A.M., Schaefer J.R., Herzum M., Maisch B., and Hofbauer L.C. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88 3 (2003) 1024-1028
171. Kiechl S., Schett G., Wenning G., Redlich K., Oberhollenzer M., Mayr A., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109 18 (2004) 2175-2180
172. Avbersek-Luznik I., Malesic I., Rus I., and Marc J. Increased levels of osteoprotegerin in hemodialysis patients. Clin Chem Lab Med 40 10 (2002) 1019-1023
173. Kazama J.J., Shigematsu T., Yano K., Tsuda E., Miura M., Iwasaki Y., et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 39 3 (2002) 525-532
174. Nitta K., Akiba T., Suzuki K., Uchida K., Ogawa T., Majima K., et al. Assessment of coronary artery calcification in hemodialysis patients using multi-detector spiral CT scan. Hypertens Res 27 8 (2004) 527-533
175. Morena M., Terrier N., Jaussent I., Leray-Moragues H., Chalabi L., Rivory J.P., et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 17 1 (2006) 262-270
176. Hjelmesaeth J., Ueland T., Flyvbjerg A., Bollerslev J., Leivestad T., Jenssen T., et al. Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. J Am Soc Nephrol 17 6 (2006) 1746-1754
177. Keso T., Perola M., Laippala P., Ilveskoski E., Kunnas T.A., Mikkelsson J., et al. Polymorphisms within the tumor necrosis factor locus and prevalence of coronary artery disease in middle-aged men. Atherosclerosis 154 3 (2001) 691-697
178. Strom A., Franzen A., Wangnerud C., Knutsson A.K., Heinegard D., and Hultgardh-Nilsson A. Altered vascular remodeling in osteopontin-deficient atherosclerotic mice. J Vasc Res 41 4 (2004) 314-322
179. Soufi M., Schoppet M., Sattler A.M., Herzum M., Maisch B., Hofbauer L.C., et al. Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab 89 8 (2004) 3764-3768
180. Oldberg A., Franzen A., and Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 83 23 (1986) 8819-8823
181. Chellaiah M.A., Kizer N., Biswas R., Alvarez U., Strauss-Schoenberger J., Rifas L., et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 14 1 (2003) 173-189
182. Steitz S.A., Speer M.Y., McKee M.D., Liaw L., Almeida M., Yang H., et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 161 6 (2002) 2035-2046
183. Spicer S.S., Lewis S.E., Tashian R.E., and Schulte B.A. Mice carrying a CAR-2 null allele lack carbonic anhydrase II immunohistochemically and show vascular calcification. Am J Pathol 134 4 (1989) 947-954
184. Wada T., McKee M.D., Steitz S., and Giachelli C.M. Calcification of vascular smooth muscle cell cultures: Inhibition by osteopontin. Circ Res 84 2 (1999) 166-178
185. Nakamura H., Honda H., Inada Y., Kato N., Kato K., Kitazawa K., et al. Osteopontin expression in vascular smooth muscle cells in patients with end-stage renal disease. Ther Apher Dial 10 3 (2006) 273-277
186. Speer M.Y., McKee M.D., Guldberg R.E., Liaw L., Yang H.Y., Tung E., et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: Evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 196 8 (2002) 1047-1055
187. Speer M.Y., Chien Y.C., Quan M., Yang H.Y., Vali H., McKee M.D., et al. Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro. Cardiovasc Res 66 2 (2005) 324-333
188. Giachelli C.M., Bae N., Almeida M., Denhardt D.T., Alpers C.E., and Schwartz S.M. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 92 4 (1993) 1686-1696
189. O'Brien E.R., Garvin M.R., Stewart D.K., Hinohara T., Simpson J.B., Schwartz S.M., et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 14 10 (1994) 1648-1656
190. O'Brien K.D., Kuusisto J., Reichenbach D.D., Ferguson M., Giachelli C., Alpers C.E., et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 92 8 (1995) 2163-2168
191. Ikeda T., Shirasawa T., Esaki Y., Yoshiki S., and Hirokawa K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 92 6 (1993) 2814-2820
192. Hirota S., Imakita M., Kohri K., Ito A., Morii E., Adachi S., et al. Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am J Pathol 143 4 (1993) 1003-1008
193. Fitzpatrick L.A., Severson A., Edwards W.D., and Ingram R.T. Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. J Clin Invest 94 4 (1994) 1597-1604
194. Srivatsa S.S., Harrity P.J., Maercklein P.B., Kleppe L., Veinot J., Edwards W.D., et al. Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves. J Clin Invest 99 5 (1997) 996-1009
195. Nitta K., Ishizuka T., Horita S., Hayashi T., Ajiro A., Uchida K., et al. Soluble osteopontin and vascular calcification in hemodialysis patients. Nephron 89 4 (2001) 455-458
196. Denhardt D.T., and Noda M. Osteopontin expression and function: Role in bone remodeling. J Cell Biochem Suppl 30-31 (1998) 92-102
197. Murry C.E., Giachelli C.M., Schwartz S.M., and Vracko R. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol 145 6 (1994) 1450-1462
198. Weber G.F., Ashkar S., Glimcher M.J., and Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271 5248 (1996) 509-512
199. Jansson M., Panoutsakopoulou V., Baker J., Klein L., and Cantor H. Cutting edge: Attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J Immunol 168 5 (2002) 2096-2099
200. Mazzali M., Kipari T., Ophascharoensuk V., Wesson J.A., Johnson R., and Hughes J. Osteopontin-a molecule for all seasons. Q J Med 95 1 (2002) 3-13
201. Taylor Jr. F.B., Peer G.T., Lockhart M.S., Ferrell G., and Esmon C.T. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 97 6 (2001) 1685-1688
202. Gravallese E.M. Osteopontin: A bridge between bone and the immune system. J Clin Invest 112 2 (2003) 147-149
203. Ohmori R., Momiyama Y., Taniguchi H., Takahashi R., Kusuhara M., Nakamura H., et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 170 2 (2003) 333-337
204. Golledge J., McCann M., Mangan S., Lam A., and Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 35 7 (2004) 1636-1641
205. Matsui Y., Rittling S.R., Okamoto H., Inobe M., Jia N., Shimizu T., et al. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 23 6 (2003) 1029-1034
206. Shi Y., and Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113 6 (2003) 685-700
207. Hruska K.A., Mathew S., and Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 97 2 (2005) 105-114
208. Massague J., Seoane J., and Wotton D. Smad transcription factors. Genes Dev 19 23 (2005) 2783-2810
209. Galvin K.M., Donovan M.J., Lynch C.A., Meyer R.I., Paul R.J., Lorenz J.N., et al. A role for smad6 in development and homeostasis of the cardiovascular system. Nat Genet 24 2 (2000) 171-174
210. Luo G., Hofmann C., Bronckers A.L., Sohocki M., Bradley A., and Karsenty G. BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning. Genes Dev 9 22 (1995) 2808-2820
211. Wang S.N., Lapage J., and Hirschberg R. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 12 11 (2001) 2392-2399
212. Lund R.J., Davies M.R., and Hruska K.A. Bone morphogenetic protein-7: An anti-fibrotic morphogenetic protein with therapeutic importance in renal disease. Curr Opin Nephrol Hypertens 11 1 (2002) 31-36
213. Li T., Surendran K., Zawaideh M.A., Mathew S., and Hruska K.A. Bone morphogenetic protein 7: A novel treatment for chronic renal and bone disease. Curr Opin Nephrol Hypertens 13 4 (2004) 417-422
214. Wang S., Chen Q., Simon T.C., Strebeck F., Chaudhary L., Morrissey J., et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 63 6 (2003) 2037-2049
215. Dorai H., Vukicevic S., and Sampath T.K. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 184 1 (2000) 37-45
216. Ishimura E., and Shioi A. Mechanism of arterial calcification with regards to atherosclerotic calcification and medial artery calcification. Clin Calcium 15 7 (2005) 137-142
217. Towler D.A. Inorganic pyrophosphate: A paracrine regulator of vascular calcification and smooth muscle phenotype. Arterioscler Thromb Vasc Biol 25 4 (2005) 651-654
218. Fleisch H., Russell R.G., and Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212 5065 (1966) 901-903
219. Johnson K., Goding J., Van Etten D., Sali A., Hu S.I., Farley D., et al. Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res 18 6 (2003) 994-1004
220. Rutsch F., Ruf N., Vaingankar S., Toliat M.R., Suk A., Hohne W., et al. Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 34 4 (2003) 379-381
221. Harmey D., Hessle L., Narisawa S., Johnson K.A., Terkeltaub R., and Millan J.L. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: An integrated model of the pathogenesis of mineralization disorders. Am J Pathol 164 4 (2004) 1199-1209
222. Johnson K., Polewski M., van Etten D., and Terkeltaub R. Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/- mice. Arterioscler Thromb Vasc Biol 25 4 (2005) 686-691
223. Ho A.M., Johnson M.D., and Kingsley D.M. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 289 5477 (2000) 265-270
224. Russell R.G., Bisaz S., and Fleisch H. Pyrophosphate and diphosphonates in calcium metabolism and their possible role in renal failure. Arch Intern Med 124 5 (1969) 571-577
225. Meyer J.L. Can biological calcification occur in the presence of pyrophosphate?. Arch Biochem Biophys 231 1 (1984) 1-8
226. Francis M.D., Russell R.G., and Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165 899 (1969) 1264-1266
227. Rutsch F., Vaingankar S., Johnson K., Goldfine I., Maddux B., Schauerte P., et al. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol 158 2 (2001) 543-554
228. Terkeltaub R.A. Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol 281 1 (2001) C1-C11
229. Lomashvili K.A., Khawandi W., and O'Neill W.C. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 16 8 (2005) 2495-2500
230. Ziolkowska H., Wojnar J., Panczyk-Tomaszewska M., and Roszkowska-Blaim M. [Fetuin A in children with renal diseases]. Przegl Lek 63 Suppl. 3 (2006) 54-56
231. Honda H., Qureshi A.R., Heimburger O., Barany P., Wang K., Pecoits-Filho R., et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 47 1 (2006) 139-148
232. Cozzolino M., Galassi A., Biondi M.L., Turri O., Papagni S., Mongelli N., et al. Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients. Am J Nephrol 26 5 (2006) 423-429
233. Coen G., Ballanti P., Balducci A., Grandi F., Manni M., Mantella D., et al. Renal osteodystrophy: Alpha-Heremans Schmid glycoprotein/fetuin-A, matrix GLA protein serum levels, and bone histomorphometry. Am J Kidney Dis 48 1 (2006) 106-113
234. Coen G., Manni M., Agnoli A., Balducci A., Dessi M., De Angelis S., et al. Cardiac calcifications: Fetuin-A and other risk factors in hemodialysis patients. ASAIO J 52 2 (2006) 150-156
235. Jung H.H., Kim S.W., and Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant 21 7 (2006) 1915-1920
236. Russo D., Corrao S., Miranda I., Ruocco C., Manzi S., Elefante R., et al. Progression of coronary artery calcification in predialysis patients. Am J Nephrol 27 2 (2007) 152-158
237. Caglar K., Yilmaz M.I., Saglam M., Cakir E., Kilic S., Eyileten T., et al. Endothelial dysfunction and fetuin A levels before and after kidney transplantation. Transplantation 83 4 (2007) 392-397
238. Hermans M.M., Kooman J.P., Brandenburg V., Ketteler M., Damoiseaux J.G., Cohen Tervaert J.W., et al. Spatial inhomogeneity of common carotid artery intima-media is increased in dialysis patients. Nephrol Dial Transplant 22 4 (2007) 1205-1212
239. Cozzolino M., Galassi A., Biondi M.L., Butti A., Russo M., Longhini C., et al. Decreased serum fetuin-A levels after a single haemodialysis session. Nephrol Dial Transplant 22 1 (2007) 290-291
240. Kalabay L., Jakab L., Cseh K., Pozsonyi T., and Jakab L.A. Correlations between serum alpha 2-HS-glycoprotein concentration and conventional laboratory parameters in systemic lupus erythematosus. Acta Med Hung 47 1-2 (1990) 53-64
241. Mori K., Emoto M., Yokoyama H., Araki T., Teramura M., Koyama H., et al. Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care 29 2 (2006) 468
242. Hendig D., Schulz V., Arndt M., Szliska C., Kleesiek K., and Gotting C. Role of serum fetuin-A, a major inhibitor of systemic calcification, in pseudoxanthoma elasticum. Clin Chem 52 2 (2006) 227-234
243. Mori K., Emoto M., Araki T., Yokoyama H., Teramura M., Lee E., et al. Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol 66 2 (2007) 246-250
244. Kaden J.J., Reinohl J.O., Blesch B., Brueckmann M., Haghi D., Borggrefe M., et al. Systemic and local levels of fetuin-A in calcific aortic valve stenosis. Int J Mol Med 20 2 (2007) 193-197